

Technology/ Title	DBPR22998/ A QPCTL (IsoQC) Inhibitor Targeting CD47-SIRPα Axis for Cancer Immunotherapy		
Subtitle			
Technology Type	<input type="checkbox"/> Biotechnology <input checked="" type="checkbox"/> Pharmaceutical		<input type="checkbox"/> Device/Diagnostics
Contact Person	Name: Cindy Hsieh		Title: Manager
	Telephone(work): +886-37246166-33209		Mobile:
	Email: wenchuan@nhri.edu.tw		
Link			
Technology Description	<p><b>Introduction:</b></p> <p>CD47-SIRPα “Do-not-eat- me” signaling axis is myeloid-specific innate immune checkpoint. Cancer cells express CD47 on the cell surface enable them to evade detection by the innate immune system and thus avoid destruction by macrophages.</p> <p><b><u>Key Features</u></b></p> <ul style="list-style-type: none"> <li>• An orally bioavailable small molecule isoQC (QPCTL) inhibitor modulating CD47-SIRPα “Do not eat me” cancer immune checkpoint activities</li> <li>• Target post translational modification process of CD47 protein synthesis</li> <li>• Opportunity for combination with anti-tumor antibody therapeutics, chemotherapy, radiation and immune checkpoint inhibitors (ICIs)</li> </ul> <p><b><u>Pharmaceutical Development</u></b></p> <ul style="list-style-type: none"> <li>• Crystalline form identified; physicochemical properties/pre-formulation/formulation evaluation completed</li> <li>• Preclinical kilogram-scale production of the active pharmaceutical ingredient (API) available.</li> <li>• Non-GLP 14-day repeated-dose toxicity studies in rats completed, providing valuable insights into the safety profile.</li> </ul> <p><b><u>Market Positioning</u></b></p> <ul style="list-style-type: none"> <li>• As opposed to anti-CD47 antibody approaches in clinical development, our small molecule isoQC (QPCTL) inhibitor DBPR22998 is a best-in-class and innovative therapeutic approach for boosting the efficiency of cancer immunotherapy while avoiding anti-CD47 antibody-induced anemia and thrombocytopenia</li> </ul>		
Intellectual Property	US/PCT patents		

Key Publications	NA
Business Opportunity	Technology transfer; Co-development

## DBPR22998: Mechanism of Action

